ATTARBASCHI, Andishe, Elisa CARRARO, Ousama ABLA, Shlomit BARZILAI-BIRENBOIM, Simon BOMKEN, Laurence BRUGIERES, Eva BUBANSKA, Birgit BURKHARDT, Alan k.S. CHIANG, Monika CSOKA, Alina FEDOROVA, Janez JAZBEC, Edita KABICKOVA, Zdenka KŘENOVÁ, Jelena LAZIC, Jan LOEFFEN, Georg MANN, Felix NIGGLI, Natalia MIAKOVA, Tomoo OSUMI, Leila RONCERAY, Anne UYTTEBROECK, Denise WILLIAMS, Wilhelm WOESSMANN, Grazyna WROBEL a Marta PILLON. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. Pavia: Ferrata Storti Foundation, 2016, roč. 101, č. 12, s. 1581-1591. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2016.147116.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents
Autoři ATTARBASCHI, Andishe (40 Rakousko), Elisa CARRARO (380 Itálie), Ousama ABLA (124 Kanada), Shlomit BARZILAI-BIRENBOIM (376 Izrael), Simon BOMKEN (826 Velká Británie a Severní Irsko), Laurence BRUGIERES (250 Francie), Eva BUBANSKA (703 Slovensko), Birgit BURKHARDT (276 Německo), Alan k.S. CHIANG (344 Hongkong), Monika CSOKA (348 Maďarsko), Alina FEDOROVA (112 Bělorusko), Janez JAZBEC (705 Slovinsko), Edita KABICKOVA (203 Česká republika), Zdenka KŘENOVÁ (203 Česká republika, garant, domácí), Jelena LAZIC (688 Srbsko), Jan LOEFFEN (528 Nizozemské království), Georg MANN (40 Rakousko), Felix NIGGLI (756 Švýcarsko), Natalia MIAKOVA (643 Rusko), Tomoo OSUMI (392 Japonsko), Leila RONCERAY (40 Rakousko), Anne UYTTEBROECK (56 Belgie), Denise WILLIAMS (826 Velká Británie a Severní Irsko), Wilhelm WOESSMANN (276 Německo), Grazyna WROBEL (616 Polsko) a Marta PILLON (380 Itálie).
Vydání Haematologica, Pavia, Ferrata Storti Foundation, 2016, 0390-6078.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Itálie
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 7.702
Kód RIV RIV/00216224:14110/16:00092612
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3324/haematol.2016.147116
UT WoS 000392584400018
Klíčová slova anglicky Non-Hodgkin lymphoma
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 4. 4. 2017 13:46.
Anotace
Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers, by the two largest consortia in childhood non-Hodgkin lymphoma, the European Intergroup for Childhood non-Hodgkin Lymphoma, and the international Berlin-Frankfurt-Münster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124, 58%); b) primary immunodeficiencies not further specified (n=27, 13%); c) genetic diseases with no increased cancer risk (n=40, 19%); and d) non-classifiable conditions (n=22, 10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32), Nijmegen breakage syndrome (n=26), constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk, 5-year event-free survival and overall survival rates were 40%±4% and 51%±4%, respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%±4% and 24%±4%, respectively. Ten-year incidence of second malignancy was 24%±5% and 7-year overall survival of the 21 patients with a second malignancy was 41%±11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.
VytisknoutZobrazeno: 27. 7. 2024 20:31